|Bid||9.90 x 3200|
|Ask||10.04 x 4000|
|Day's Range||9.78 - 10.02|
|52 Week Range||4.81 - 13.20|
|Beta (5Y Monthly)||1.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2021 - Mar 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.50|
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences: